JP6827467B2 - ウイルス塞栓術のための組成物および方法 - Google Patents

ウイルス塞栓術のための組成物および方法 Download PDF

Info

Publication number
JP6827467B2
JP6827467B2 JP2018517499A JP2018517499A JP6827467B2 JP 6827467 B2 JP6827467 B2 JP 6827467B2 JP 2018517499 A JP2018517499 A JP 2018517499A JP 2018517499 A JP2018517499 A JP 2018517499A JP 6827467 B2 JP6827467 B2 JP 6827467B2
Authority
JP
Japan
Prior art keywords
virus
tumor
composition
oncolytic
embolization
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018517499A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018517778A (ja
JP2018517778A5 (https=
Inventor
ファン，テ，ホ
イ，ナム，ヒ
チョ，モン
ジョン，ウンベ
ビョン，ドゥ，ジン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sillajen Inc
Original Assignee
Sillajen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sillajen Inc filed Critical Sillajen Inc
Publication of JP2018517778A publication Critical patent/JP2018517778A/ja
Publication of JP2018517778A5 publication Critical patent/JP2018517778A5/ja
Application granted granted Critical
Publication of JP6827467B2 publication Critical patent/JP6827467B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/763—Herpes virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A61K39/165—Mumps or measles virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24171—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2018517499A 2015-06-19 2016-06-17 ウイルス塞栓術のための組成物および方法 Active JP6827467B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562182383P 2015-06-19 2015-06-19
US62/182,383 2015-06-19
PCT/IB2016/000993 WO2017037523A1 (en) 2015-06-19 2016-06-17 Compositions and methods for viral embolization

Publications (3)

Publication Number Publication Date
JP2018517778A JP2018517778A (ja) 2018-07-05
JP2018517778A5 JP2018517778A5 (https=) 2019-07-18
JP6827467B2 true JP6827467B2 (ja) 2021-02-10

Family

ID=58186857

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018517499A Active JP6827467B2 (ja) 2015-06-19 2016-06-17 ウイルス塞栓術のための組成物および方法

Country Status (8)

Country Link
US (1) US10517910B2 (https=)
EP (1) EP3310383B1 (https=)
JP (1) JP6827467B2 (https=)
KR (1) KR102735275B1 (https=)
CN (1) CN108025056B (https=)
AU (1) AU2016313969B2 (https=)
ES (1) ES2795010T3 (https=)
WO (1) WO2017037523A1 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4122492A1 (en) 2015-02-25 2023-01-25 Memorial Sloan Kettering Cancer Center Use of inactivated nonreplicating modified vaccinia virus ankara (mva)as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors
KR20180006916A (ko) 2015-04-17 2018-01-19 메모리얼 슬로안-케터링 캔서 센터 고형 종양에 대한 면역치료제로서 mva 또는 mva델타e3l의 용도
CN108025056B (zh) 2015-06-19 2022-01-14 新罗杰股份有限公司 用于病毒栓塞的组合物和方法
JP7025339B2 (ja) 2016-02-25 2022-02-24 メモリアル スローン ケタリング キャンサー センター 癌免疫療法のための、チミジンキナーゼの欠失を伴い、ヒトｆｌｔ３ｌまたはｇｍ－ｃｓｆの発現を伴うかまたは伴わない、複製可能な弱毒化ワクシニアウイルス
CN109152827B (zh) 2016-02-25 2023-07-21 纪念斯隆凯特琳癌症中心 重组mva或表达人flt3l的mvaδe3l及其作为抗固体肿瘤的免疫治疗剂的用途
KR102190326B1 (ko) * 2016-07-21 2020-12-11 코오롱생명과학 주식회사 재조합 백시니아 바이러스 및 이의 용도
EP3621646A4 (en) 2017-05-12 2021-06-02 Memorial Sloan Kettering Cancer Center VACCINIA VIRUS MUTANTS FOR CANCER IMMUNOTHERAPY
CN109554353B (zh) * 2017-09-26 2021-08-06 杭州康万达医药科技有限公司 分离的重组溶瘤痘病毒、药物组合物及其在治疗肿瘤和/或癌症的药物中的用途
KR20190059421A (ko) * 2017-11-23 2019-05-31 주식회사 바이오녹스 항암바이러스의 간동맥 투여를 이용한 간암 치료방법
CA3106202A1 (en) 2018-07-13 2020-01-16 Arizona Board Of Regents On Behalf Of Arizona State University Methods of treating cancer with tnf expressing myxoma virus
BR112021004692A2 (pt) 2018-09-15 2021-06-08 Memorial Sloan Kettering Cancer Center poxvírus recombinantes para imunoterapia de câncer
US20240024393A1 (en) * 2019-01-25 2024-01-25 Virocure, Inc. Pharmaceutical composition for preventing or treating cancer, comprising squirrel fibroma virus and reovirus
JP2022520220A (ja) 2019-02-14 2022-03-29 イグナイト イミュノセラピー インク 組換えワクシニアウイルスおよびその使用方法
MX2022002547A (es) * 2019-09-02 2022-05-18 Univ Arizona State Una nueva plataforma de virus oncoliticos para tratar canceres con virus myxoma.
DE102020101197A1 (de) * 2020-01-20 2021-07-22 Charité - Universitätsmedizin Berlin Medizinprodukt zur Arzneimittelabgabe mit verstärkter Wirkung
TW202217002A (zh) 2020-07-13 2022-05-01 法商傳斯堅公司 免疫抑制之治療
WO2023213763A1 (en) 2022-05-02 2023-11-09 Transgene Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab
WO2023213764A1 (en) 2022-05-02 2023-11-09 Transgene Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf
CN116942888B (zh) * 2023-09-11 2026-03-24 科睿驰（深圳）医疗科技发展有限公司 淀粉水凝胶栓塞微球及其制备方法
WO2026041811A1 (en) 2024-08-23 2026-02-26 Transgene Recombinant poxvirus and method for regulating the expression of toxic conditional gene products of said recombinant poxvirus in a producing cell

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5073627A (en) 1989-08-22 1991-12-17 Immunex Corporation Fusion proteins comprising GM-CSF and IL-3
JPH07509122A (ja) 1992-04-08 1995-10-12 ザ　ガバメント　オブ　ザ　ユナイテッド　ステイツ　オブ　アメリカ，アズ　レプリゼンテッド　バイ　ザ　セクレター，デパートメント　オブ　ヘルス　アンド　ヒューマン　サービシーズ 野生型麻疹ウイルス糖タンパク質：ワクチンおよびその検出方法
FR2736358B1 (fr) 1995-07-05 1997-09-26 Agronomique Inst Nat Rech Virus myxomateux recombinant
AU8877098A (en) 1997-09-05 1999-03-29 Nycomed Imaging As Polymer particles made of polyvinyl alcohol and comprising contrast agent for chemoembolization
FR2784580B1 (fr) * 1998-10-16 2004-06-25 Biosepra Inc Microspheres de polyvinyl-alcool et procedes de fabrication de celles-ci
KR100872884B1 (ko) * 2000-03-24 2008-12-10 바이오스피어 메디칼 인코포레이티드 능동 색전화용 미소구
JP2004510724A (ja) * 2000-10-06 2004-04-08 ヤゴテック　アーゲー 分子量の低下した澱粉からなる微粒子中に埋め込まれた免疫学的活性物質を含むワクチン組成物
DE03722131T1 (de) 2002-05-09 2005-09-15 Oncolytics Biotech, Inc., Calgary Methode zur schmerzbekämpfung mit onkolytischen viren
EP2269619A1 (en) * 2002-08-12 2011-01-05 Jennerex Biotherapeutics ULC Methods and compositions concerning poxviruses and cancer
KR101772375B1 (ko) * 2005-09-07 2017-08-29 신라젠(주) Ｇｍ-ｃｓｆ를 발현하는 폭스바이러스를 사용한 전이성 및/또는 전신 파종성 암의 전신 치료법
US8980246B2 (en) * 2005-09-07 2015-03-17 Sillajen Biotherapeutics, Inc. Oncolytic vaccinia virus cancer therapy
JPWO2008105504A1 (ja) * 2007-03-01 2010-06-03 コスメディ製薬株式会社 経皮免疫製剤、その製造方法及びそれを用いた経皮免疫方法
KR20080084528A (ko) * 2007-03-15 2008-09-19 제네렉스 바이오테라퓨틱스 인크. 종양살상형 백시니아 바이러스 암 치료
BR112012005774B8 (pt) * 2009-09-14 2023-02-14 Jennerex Inc uso de um inibidor de quinase antiangiogênico no tratamento de câncer
WO2011135734A1 (ja) * 2010-04-28 2011-11-03 株式会社アルファ・ナノ・メディカ ウイルスの複合体、それを含有する治療薬及び治療方法
US9724421B2 (en) * 2010-11-29 2017-08-08 Centre Hospitalier Universitaire Vaudois Chemoembolization composition comprising anti-angiogenic agents
KR101942237B1 (ko) * 2011-01-04 2019-01-25 신라젠(주) 종양 항원에 대한 항체의 생산 및 종양용해 우두 바이러스의 투여에 의한 종양 특이적 보체 의존적 세포독성의 생산
EP2739293B1 (en) 2011-08-05 2020-06-10 SillaJen Biotherapeutics, Inc. Methods and compositions for production of vaccina virus
WO2014031693A1 (en) * 2012-08-20 2014-02-27 Genelux Corporation Compositions containing protein polymers and vaccinia virus, and methods of use thereof
US20140194370A1 (en) * 2013-01-08 2014-07-10 University Of Utah Research Foundation Silk-elastin like protein polymers for embolization and chemoembolization to treat cancer
CN108025056B (zh) 2015-06-19 2022-01-14 新罗杰股份有限公司 用于病毒栓塞的组合物和方法
HK1255192A1 (zh) * 2015-09-08 2019-08-09 Sillajen, Inc. 表达细胞因子和羧酸酯酶的修饰的溶瘤痘苗病毒及其使用方法

Also Published As

Publication number Publication date
WO2017037523A1 (en) 2017-03-09
ES2795010T3 (es) 2020-11-20
US20180303886A1 (en) 2018-10-25
EP3310383A4 (en) 2019-02-27
CA2990133A1 (en) 2017-03-09
CN108025056A (zh) 2018-05-11
EP3310383A1 (en) 2018-04-25
JP2018517778A (ja) 2018-07-05
HK1252004A1 (en) 2019-05-10
KR20180021083A (ko) 2018-02-28
EP3310383B1 (en) 2020-02-19
AU2016313969B2 (en) 2021-12-23
CN108025056B (zh) 2022-01-14
KR102735275B1 (ko) 2024-11-29
AU2016313969A1 (en) 2018-02-15
US10517910B2 (en) 2019-12-31

Similar Documents

Publication Publication Date Title
JP6827467B2 (ja) ウイルス塞栓術のための組成物および方法
KR101869235B1 (ko) 종양 용해 백시니아 바이러스 암 치료법
US8227440B2 (en) Use of Myxoma virus for the therapeutic treatment of cancer and chronic viral infection
CN101137748B (zh) 粘液瘤病毒与雷帕霉素的组合在治疗性处理中的应用
Meerani et al. Oncolytic viruses in cancer therapy
CA2990133C (en) Compositions and methods for viral embolization
HK1252004B (en) Compositions and methods for viral embolization
Saha et al. Viral oncolysis of glioblastoma
CN100379453C (zh) 粘液瘤病毒在治疗癌症和慢性病毒感染中的用途
Doty Treatment of murine tumors with recombinant Myxoma viruses
HK1081099B (en) Use of myxoma virus for therapeutic treatment of cancer and chronic viral infection

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190614

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190614

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200602

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200824

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201110

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201211

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210106

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210119

R150 Certificate of patent or registration of utility model

Ref document number: 6827467

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250